Cellular mechanism for granulocyte-colony stimulating factor in the prevention of graft-versus-host disease in combined bone marrow and peripheral blood transplantation for hematological malignancies: The composition in collection

Transfusion and Apheresis Science

Volumn 48, Issue 1, 2013, Pages 3-9

  Zhang, Cheng ^a   Zhang, Xi ^a   Chen, Xing Hua ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bone marrow; Graft versus host disease; Granulocyte colony stimulating factor; Haploidentical mismatched related transplantation

Indexed keywords

CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRAFT VERSUS HOST DISEASE; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CELL MATURATION; CELL PROLIFERATION; CELL THERAPY; DENDRITIC CELL; DONOR; ENDOTHELIUM CELL; FIBROBLAST; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; MESENCHYMAL STEM CELL TRANSPLANTATION; MONOCYTE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REVIEW; STEM CELL MOBILIZATION; SURVIVAL TIME; T LYMPHOCYTE; TREATMENT OUTCOME;

BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84873132745     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2012.08.004     Document Type: Review

References (115)

1. Pasquini M.C. Impact of graft-versus-host disease on survival. Best Prac Res Clin Haematol 2008, 21(2):193-204.
2. Socie G., Stone J.V., Wingard J.R., et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. N Engl J Med 1999, 341(1):14-21.
3. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75(3):555-562.
4. Pasquini M.C., Wang Z., Schneider L. Current use and outcome of hematopoietic stem cell transplantation: part I-CIBMTR Summary Slides, 2007. CIBMTR Newsl [serial online] 2007, 13(2):5-9.
5. Sorror M.L., Leisenring W., Deeg H.J., et al. Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Biol Blood Marrow Transplant 2005, 11(10):814-815.
6. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 96(6):2062-2068.
7. Wagner J.E., Thompson J.S., Carter S.L., et al. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multicentre, randomised phase II-III trial. Lancet 2005, 366(9487):733-741.
8. Beatty P.G., Clift R.A., Mickelson E.M., et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985, 313(13):765-771.
9. Aversa F., Terenzi A., Carotti A., et al. Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia. J Clin Oncol 1999, 17(5):1545-1550.
10. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005, 23(15):3447-3454.
11. Aversa F., Tabilio A., Velardi A., et al. Hematopoietic stem cell transplantation from alternative donors for high-risk acute leukemia: the haploidentical option. Curr Stem Cell Res Ther 2007, 2(1):105-112.
12. + selected progenitor cells from alternative donors. Br J Haematol 2004, 124(1):72-79.
13. Lang P., Greil J., Bader P., et al. Long-term outcome after haploidentical stem cell transplantation in children. Blood Cell Mol Dis 2004, 33(3):281-287.
14. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14(6):641-650.
15. Brodsky R.A., Luznik L., Bolanos-Meade J., et al. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant 2008, 42(8):523-527.
16. Bishop M.R., Henslee-Downey P.J., Anderson J.R., et al. Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors. Bone Marrow Transplant 1996, 18(4):747-753.
17. Schattenberg A.V., Dolstra H. Cellular adoptive immunotherapy after allogeneic stem cell transplantation. Curr Opin Oncol 2005, 17(6):617-621.
18. Ruggeri L., Capanni M., Casucci M., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999, 94(1):333-339.
19. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295(5562):2097-2100.
20. Zhao X.Y., Huang X.J., Liu K.Y., et al. Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients. Eur J Haematol 2007, 78(4):338-346.
21. Aversa F., Reisner Y., Martelli M.F. The haploidentical option for high-risk haematological malignancies. Blood Cell Mol Dis 2008, 40(1):8-12.
22. Huang X.J. HLA-mismatched/haploidentical hematopoietic stem cell transplantation: a field in which Chinese doctors are making great contributions. Chin Med J 2010, 123(10):1235-1240.
23. Passweg J.R. Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol 2006, 19(4):811-824.
24. Chen X., Zhang C., Zhang X., et al. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 2009, 15(2):266-273.
25. Zhang C., Chen X.H., Zhang X., et al. Stem cell collection in unmanipulated HLA-haploidentical/mismatched related transplantation with combined granulocyte-colony stimulating factor-mobilised blood and bone marrow for patients with hematologic malignancies: the impact of donor characteristics and procedural settings. Transfus Med 2010, 20(3):169-177.
26. Chen X.H., Zhang C., Zhang X., et al. Cost and outcome in stem cells collection on HLA-haploidentical/ mismatched related transplantation with combined granulocyte colony stimulating factor mobilized blood and bone marrow for patients with hematologic malignancies. Transfus Apher Sci 2010, 43(1):21-28.
27. Chen X.H., Gao L., Zhang X., et al. HLA-haploidentical blood and bone marrow transplantation with anti-thymocyte globulin: long-term comparison with HLA-identical sibling transplantation. Blood Cell Mol Dis 2009, 43(1):98-104.
28. Huang X.J., Chang Y.J., Zhao X.Y. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transplant Immunol 2007, 17(3):193-197.
29. Lu D.P., Dong L.J., Wu T., et al. Conditioning including antithymocyte HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2004, 107(8):3065-3073.
30. Huang X.J., Han W., Xu L.P., et al. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease. Chin Med J 2004, 117(12):1778-1785.
31. + cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin. Biol Blood Marrow Transplant 2007, 13(12):1515-1524.
32. Guo M., Sun Z., Sun Q.Y., et al. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD. Biol Blood Marrow Transplant 2009, 15(8):930-937.
33. Wang Y., Chen F., Han Y., et al. Partially matched related hematopoietic stem cell transplantation without ex vivo T cell depletion compared with matched unrelated transplantation in adult patients with hematologic malignancies. Biol Blood Marrow Transplant 2009, 15(10):1258-1264.
34. Blazar B.R., Taylor P.A., Linsley P.S., et al. In vivo blockade of CD28/CTLA4:B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 1994, 83(12):3815-3825.
35. Guinan E.C., Boussiotis V.A., Neuberg D., et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999, 340(22):1704-1714.
36. Tanaka J., Asaka M., Imamura M. T-cell co-signalling molecules in graft-versus-host disease. Ann Hematol 2000, 79(6):283-290.
37. Harding F.A., McArthur J.G., Gross J.A., et al. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T cell clones. Nature 1992, 356(6370):607-609.
38. Rutella S., Zavala F., Daneses S., et al. Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J Immunol 2005, 175(11):7085-7091.
39. Huang X.J., Chang Y.J., Zhao X.Y. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 2004, 89(12):1517-1524.
40. Tanaka J., Mielcarek M., Torok-Storb B. Impaired induction of the CD28-responsive complex in granulocyte colony-stimulating factor mobilized CD4 T cells. Blood 1998, 91(1):347-352.
41. Mielcarek M., Graf L., Johnson G., et al. Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T cell proliferation. Blood 1998, 92(1):215-222.
42. + cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 1997, 89(5):1629-1634.
43. + T cell apoptosis following stem cell transplantation. Cancer Res 1999, 59(13):3107-3111.
44. Rodriguez P.C., Zea A.H., DeSalvo J., et al. l-Arginine consumption by macrophages modulates the expression of CD3ζ-chain in T lymphocytes. J Immunol 2003, 171(3):1232-1239.
45. Rodriguez P.C., Quiceno D.G., Zabaleta J., et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T cell receptor expression and antigen-specific T cell responses. Cancer Res 2004, 64(16):5839-5849.
46. +NKT cells. J Immunol 2004, 173(3):4960-4966.
47. Tanaka J., Toubai T., Tsutsumi Y., et al. Cytolytic activity and regulatory functions of inhibitory NK cell receptor-expressing T cells expanded from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 2004, 104(3):768-774.
48. + T cells reciprocally regulate acute graft versus host disease. J Exp Med 1999, 189(7):1073-1081.
49. - alpha beta bone marrow T cells with suppressor activity. J Immunol 1992, 148(2):373-380.
50. +) in the blood of normal donors. Blood 1997, 89(7):2586-2595.
51. Rutella S., Rumi C., Testa U., et al. Inhibition of lymphocyte blastogenic response in healthy donors treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF): possible role of lactoferrin and interleukin-1 receptor antagonist. Bone Marrow Transplant 1997, 20(5):355-364.
52. Rondelli D., Raspadori D., Anasetti C., et al. Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells. Bone Marrow Transplant 1998, 22(7):631-637.
53. Talmadge J.E., Reed E.C., Kessinger A., et al. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant 1996, 17(1):101-109.
54. Joshi S.S., Lynch J.C., Pavletic S.Z., et al. Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics. Blood 2001, 98(6):1963-1970.
55. Chen S.H., Li X., Huang X.J. Effect of recombinant human granulocyte colony-stimulating factor on T-lymphocyte function and the mechanism of this effect. Int J Hematol 2004, 79(2):178-184.
56. Pan L., Delmonte J., Jalonen C.K. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995, 86(12):4422-4429.
57. Krenger W., Hill G.R., Ferrara J.L.M. Cytokine cascades in acute graft-versus-host disease. Transplantation 1997, 64(4):553-558.
58. Ferrara J.L.M., Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006, 43(1):3-10.
59. Zeng D., Dejbakhsh-Jones S., Stroker S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood 1997, 90(1):453-463.
60. Krenger W., Snyder K.M., Byon J.C., et al. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host-disease. J Immunol 1995, 155(2):585-593.
61. Ramsdell F., Seaman M.S., Miller R.E., et al. Differential ability of Th1 and Th2 cells to express Fas ligand and to undergo activation-induced cell death. Int Immunol 1994, 6(10):1545-1553.
62. Luo X.H., Chang Y.J., Xu L.P., et al. The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic SCT. Bone Marrow Transplant 2009, 43(1):29-36.
63. Paust S., Cantor H. Regulatory T cells and autoimmune disease. Immunol Rev 2005, 204:195-207.
64. Rutella S., Danese S., Leone G. Regulatory T cells for immunotherapy of autoimmune diseases: from the bench to the bedside. Exp Opin Ther Patents 2005, 15(11):1595-1616.
65. Hoffman P., Eder R., Kunz-Schughart L.A., et al. Large-scale in vitro expansion of polyclonal human CD4+ CD25high regulatory T cells. Blood 2004, 104(3):895-903.
66. Clark F.J., Gregg R., Piper K., et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood 2004, 103(6):2410-2416.
67. Rutella S., Lemoli R.M. Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. Immunol Lett 2004, 94(4):11-26.
68. Jonuleit H., Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol 2003, 17:6323-6327.
69. + regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 2004, 64(22):8451-8455.
70. Rutella S., Pierelli L., Bonanno G., et al. Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood 2002, 100(7):2562-2571.
71. Morris E.S., MacDonald K.P., Rowe V., et al. Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. Blood 2004, 103(9):3573-3581.
72. Levings M.K., Sangregorio R., Galbiati F., et al. IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol 2001, 166(9):5530-5539.
73. Rutella S., Bonanno G., Pierelli L., et al. Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-α. Eur J Immunol 2004, 34(5):1291-1302.
74. Klangsinsirikul P., Russell N.H. Peripheral blood stem cell harvests from G-CSF stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cells. Exp Hematol 2002, 30(5):495-501.
75. Arpinati M., Green C.L., Heimfeld S., et al. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000, 95(8):2484-2490.
76. Pulendran B., Banchereau J., Burkeholder S., et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol 2000, 165(1):566-572.
77. hi blood dendritic cells with altered CD62L and CCR7 expression. Blood 2003, 101(6):2314-2317.
78. Toubai T., Malter C., Tawara I., et al. Immunization with host-type CD8{alpha}+ dendritic cells reduces experimental acute GVHD in an IL-10-dependent manner. Blood 2010, 115(3):724-735.
79. Fagnoni F.F., Oliviero B., Giorgiani G., et al. Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic myeloablative hematopoietic stem cell transplantation. Blood 2004, 104(1):281-289.
80. Rissoan M.C., Soumelis V., Kadowaki N., et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999, 283(5405):1183-1186.
81. Zheng H., Matte-Martone C., Li H., et al. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Blood 2008, 111(4):2476-2484.
82. Zhang Y., Joe G., Zhu J., et al. Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity. Blood 2004, 103(10):3970-3978.
83. Chen B.J., Cui X., Sempowski G.D., et al. Transfer of allogeneic CD62L memory T cells without graft-versus-host disease. Blood 2004, 103(4):1534-1541.
84. Xystrakis E., Bernard I., Dejean A.S., et al. Alloreactive CD4 T lymphocytes responsible for acute and chronic graft-versus-host disease are contained within the CD45RChigh but not the CD45RClow subset. Eur J Immunol 2004, 34(2):408-417.
85. Chen B.J., Deoliveira D., Cui X., et al. Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood 2007, 109(7):3115-3123.
86. Wysocki C.A., Panoskaltsis-Mortari A., Blazar B.R., et al. Leukocyte migration and graft-versus-host disease. Blood 2005, 105(11):4191-4199.
87. Ichiba T., Teshima T., Kuick R., et al. Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays. Blood 2003, 102(2):763-771.
88. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994, 76(2):301-314.
89. Li B., New J.Y., Tay Y.K., et al. Delaying acute graft-versus-host disease in mouse bone marrow transplantation by treating donor cells with antibodies directed at l-selectin and alpha4-integrin prior to infusion. Scand J Immunol 2004, 59(5):464-468.
90. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 2005, 35(3):225-231.
91. Preville X., Flacher M., LeMauff B., et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001, 71(3):460-468.
92. Michallet M.C., Preville X., Flacher M., et al. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 2003, 75(5):657-662.
93. Huang X.J. Current status of haploidentical stem cell transplantation for leukemia. J Hematol Oncol 2008, 1:27.
94. Bignon J.D., Gagne K. KIR matching in hematopoietic stem cell transplantation. Curr Opin Immunol 2005, 17(5):553-559.
95. Giebel S., Locatelli F., Lamparelli T., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003, 102(3):814-819.
96. Leung W., Iyengar R., Triplett B., et al. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 2005, 174(10):6540-6545.
97. Bornhauser M., Schwerdtfeger R., Martin H., et al. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 2004, 103(7):2860-2862.
98. Lowe E.J., Turner V., Handgretinger R., et al. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical pediatric bone marrow transplantation. Br J Haematol 2003, 123(2):323-326.
99. Huang X.J., Zhao X.Y., Liu D.H., et al. Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion. Leukemia 2007, 21(4):848-851.
100. Cooley S., McCullar V., Wangen R., et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005, 106(13):4370-4376.
101. Zhao X.Y., Chang Y.J., Xu L.P., et al. Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors. Bone Marrow Transplant 2009, 44(11):721-728.
102. Le Blanc K., Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11(5):321-334.
103. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363(9413):1439-1441.
104. Ringden O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81(10):1390-1397.
105. Ning H., Yang F., Jiang M., et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008, 22(3):593-599.
106. Lazarus H.M., Koc O.N., Devine S.M., et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005, 11(5):389-398.
107. Le Blanc K., Samuelsson H., Gustafsson B., et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007, 21(8):1733-1738.
108. Ball L.M., Bernardo M.E., Roelofs H., et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007, 110(7):2764-2767.
109. Brouard N., Driessen R., Short B., et al. G-CSF increases mesenchymal precursor cell numbers in the bone marrow via an indirect mechanism involving osteoclast-mediated bone resorption. Stem Cell Res 2010, 5(1):65-75.
110. Ripa R.S., Haack-Sørensen M., Wang Y., et al. Bone marrow derived mesenchymal cell mobilization by granulocyte-colony stimulating factor after acute myocardial infarction: results from the stem cells in myocardial infarction (STEMMI) trial. Circulation 2007, 116(11 Suppl 1):124-130.
111. Tatsumi K., Otani H., Sato D., et al. Granulocyte-colony stimulating factor increases donor mesenchymal stem cells in bone marrow and their mobilization into peripheral circulation but does not repair dystrophic heart after bone marrow transplantation. Circ J 2008, 72(8):1351-1358.
112. Cesselli D., Beltrami A.P., Rigo S., et al. Multipotent progenitor cells are present in human peripheral blood. Circulation Res 2009, 104(10):1225-1234.
113. Mansilla E., Marin G.H., Drago H., et al. Bloodstream cells phenotypically identical to human mesenchymal bone marrow stem cells circulate in large amounts under the influence of acute large skin damage: new evidence for their use in regenerative medicine. Transplant Proc 2006, 38(3):967-969.
114. + regulatory T-cells. Diabetes 2005, 54(1):78-84.
115. MacDonald K.P., Rowe V., Clouston A.D., et al. Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J Immunol 2005, 174(4):1841-1850.